DNA

Ginkgo BioworksC

NYSE / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

20%

Probability

Target price

$12.00

Analysis reference price unavailable

Analysis 2026-05-20 · RankAlpha Sentiment Codex

Most likely

Base case

50%

Probability

Target price

$8.00

Analysis reference price unavailable

Analysis 2026-05-20 · RankAlpha Sentiment Codex

B-

Bear case

30%

Probability

Target price

$4.00

Analysis reference price unavailable

Analysis 2026-05-20 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-05-20

AI commentary

News flow is concentrated in the May 7 Q1 filing and press release, with no analyst revision wave or clean consensus update surfaced in the packet. The read stays cautious and tentative: liquidity was preserved and burn guidance was reiterated, but core revenue fell sharply, autonomous-lab monetization is still a longer-dated thesis, and the available peer set is a loose small-cap healthcare screen rather than direct operating comparators [#8-K-2026-05-07][#10-Q-2026-05-07].

RankAlpha Sentiment Codex - 2026-05-20

Open full AI memo

Evidence flagged

peer set is too generic or lacks enough direct operating comparators; small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report

Impact

tentative

Confidence

AI events

2026-05-07eventQ1 2026 print showed weaker revenue but preserved liquidityMedium impact

The May 7 8-K/press release reported Q1 revenue of $19 million, down about 49% year over year, with the decline mainly tied to ongoing program rationalization; continuing-operations net loss was $(76.1) million, adjusted EBITDA was $(42) million, and cash, cash equivalents, and marketable securities were $373 million at March 31, 2026 [#8-K-2026-05-07][#10-Q-2026-05-07].

2026-12-31catalystAutonomous-lab scaling and partner traction remain the main long-term optionHigh impact

Management said Nebula is the world's largest autonomous lab, is targeting a doubling of its size in 2026, and is seeing Cloud Lab traction from partners such as ProQR and Amazon, which gives the stock a specific platform and partnership milestone to monitor even though near-term revenue remains small [#8-K-2026-05-07].

2026-12-31catalyst2026 cash-burn execution is the key financing and runway checkpointHigh impact

Ginkgo reaffirmed expected total 2026 cash burn of $(150) million to $(125) million after reporting $373 million of cash, cash equivalents, and marketable securities at March 31, 2026, so evidence that burn remains inside that range would support runway credibility while a miss would revive financing concerns [#8-K-2026-05-07].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-20 • Updated nightlySource: Internal modelMethodology